Business Wire CSR | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb | EmailWire | 3BLMedia | 1888PressRelease

AtriCure to Present at Piper Jaffray Healthcare Conference

WEST CHESTER, Ohio - 
      AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in 
      cardiac surgical ablation systems, today announced that it will 
      participate in the Piper Jaffray Healthcare Conference at the New York 
      Palace Hotel on Tuesday, December 1, 2009. David J. Drachman, Pr
Posted : Mon, 23 Nov 2009 20:00:58 GMT
Author : AtriCure, Inc.
Category : Press Release
News Alerts by Email ( click here )
Press Release News | Home
WEST CHESTER, Ohio - (Business Wire) AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will participate in the Piper Jaffray Healthcare Conference at the New York Palace Hotel on Tuesday, December 1, 2009. David J. Drachman, President and Chief Executive Officer, is scheduled to present at 4:00 p.m. Eastern Time.

A live audio webcast and replay of the presentation will be available for 30 days following the presentation at www.atricure.com.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator® bipolar ablation system as a treatment alternative during open heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke. The FDA has cleared the AtriCure Isolator system and AtriCure’s multifunctional pen and CoolrailTM linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure’s multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias and AtriCure’s Cryo1 system for the cryosurgical treatment of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure’s products for the treatment of AF.

AtriCure, Inc.
Julie A. Piton, Vice President and Chief Financial Officer, 513-755-4561
jpiton@atricure.com


Copyright © 2010 Business Wire. All rights reserved.
Share/Save/Bookmark

Article : AtriCure to Present at Piper Jaffray Healthcare Conference
Print this article
Share this article

Stay Updated

News gadget on your Google homepage
Subscribe to a news feed in Google Reader



Related News



Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 
 

The Earth Times
News Category

© 2010 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.